Specific hormones like PTH and fibroblast growth factor-23 add complexity to bone marker regulation in ESKD [17], posing challenges in diagnosing and treating various CKD-MBD factors associated with BMD reduction. This evidence concerns the gene FGF23 and chronic kidney disease.